[Click e-Stock] "LaserOptek, High Value-Added Disease Treatment Device Effects"

On July 1, Hana Securities expressed expectations that sales for LaserOptek will increase as the company launches high value-added disease treatment devices.

Han Yugun, a researcher at Hana Securities, stated, "The company is launching high value-added equipment focused on disease treatment devices," and explained, "Compared to skin aesthetic medical devices, disease treatment devices face less competition and have higher technological entry barriers, resulting in a higher average selling price (ASP)."

He added, "The export price of the Pallas Premium is more than three times higher than that of existing skin aesthetic medical devices," and "The marketing effects of Pallas Premium will begin to be reflected from the second quarter of this year."

He continued, "Since last year, the company has been promoting its products by participating in major medical conferences in the United States and Europe," and expressed expectations that "sales will begin to increase in earnest from the second half of this year."

Han further analyzed, "The Raman Laser is the world's first vascular treatment device and can be used to treat vascular lesions," adding, "The vascular lesion laser market is estimated to be approximately 1.6 trillion KRW." He continued, "The main competing device is the Vbeam from Candela," and emphasized, "Vbeam is more expensive than the Raman Laser and uses a liquid medium, making maintenance more complicated."